ILO delays vote on whether to cut ties with tobacco industry

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The International Labour Organization voted on Wednesday to delay the decision on whether to cut ties with Big Tobacco until November.

The decision could remove one of the tobacco industry’s final avenues of influence in the United Nations. Most other UN agencies developed firm policies against collaboration with the tobacco industry after the negotiation of the World Health Organization Framework Convention on Tobacco Control, the global anti-tobacco treaty.

The vote was originally scheduled due to public health, labor, and human rights communities escalating their call for the ILO to extricate itself from Big Tobacco, one of the deadliest industries on the planet.

Since 2015, the ILO has received more than $15 million USD from Japan Tobacco International and other tobacco corporations for programs that boost the industry’s public relations yet do little toward the ILO’s stated purpose of curbing child labor violations in tobacco fields, a problem largely caused by the tobacco industry itself.

“The ILO cannot address major human rights violations by collaborating with the perpetrators,” said Laurent Huber, executive director of Action on Smoking and Health, who helped negotiate the global tobacco treaty. “Working with the tobacco industry on child labor is like inviting the fox to consult on how best to guard the henhouse.”

United Nations officials, including the Secretariat of the FCTC, have also called on the ILO to distance itself from the tobacco industry. The ILO’s coziness with the tobacco industry violates a core tenet of the FCTC, which establishes a firewall between the tobacco industry and public health policymaking.

Child labor in tobacco production is not a problem limited to the developing world. The U.S. government has acknowledged the risks of tobacco farming to children, which includes exposure to carcinogens and acute nicotine poisoning.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login